药学学报, 2020, 55(4): 720-733
孙彦莹, 左晓芳, 展鹏, 刘新泳. 抗腺病毒药物化学研究新进展[J]. 药学学报, 2020, 55(4): 720-733.
SUN Yan-ying, ZUO Xiao-fang, ZHAN Peng, LIU Xin-yong. Recent advances in the discovery and development of adenovirus inhibitors[J]. Acta Pharmaceutica Sinica, 2020, 55(4): 720-733.

孙彦莹, 左晓芳, 展鹏, 刘新泳
山东大学药学院药物化学研究所, 化学生物学教育部重点实验室, 山东 济南 250012
关键词:    腺病毒      药物靶标      抗腺病毒药物      小分子抑制剂      药物设计     
Recent advances in the discovery and development of adenovirus inhibitors
SUN Yan-ying, ZUO Xiao-fang, ZHAN Peng, LIU Xin-yong
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology(Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China
Adenovirus is a common cause of infection in children and adults with acute respiratory tract, gastrointestinal tract and urinary tract. It can cause serious and even fatal infections in patients with low immune function. Therefore, it poses a great threat to human health. Currently, there are no specific anti-adenoviral drugs in market. With in-depth investigation of the pathogenic mechanism and biological characteristics of adenovirus, and the rapid development of drug screening technology, new generation of anti-adenovirus drug targets and related inhibitors have been discovered, providing new options for treatment. This review selects the representative case studies in recent years and summarizes the advances in anti-adenoviral medicinal chemistry.
Key words:    adenovirus    drug target    anti-adenovirus agent    small molecule inhibitor    drug design   
收稿日期: 2019-11-25
DOI: 10.16438/j.0513-4870.2019-0947
基金项目: 国家自然科学基金重点国际合作研究项目(81420108027);山东省重大科技创新工程资助(2019JZZY021011,2017CXGC1401).
通讯作者: 刘新泳,Tel:86-531-88380270,E-mail:xinyongl@sdu.edu.cn;展鹏,E-mail:zhanpeng1982@sdu.edu.cn
Email: xinyongl@sdu.edu.cn;zhanpeng1982@sdu.edu.cn
PDF(1142KB) Free
孙彦莹  在本刊中的所有文章
左晓芳  在本刊中的所有文章
展鹏  在本刊中的所有文章
刘新泳  在本刊中的所有文章

[1] Lenaerts L, De Clercq E, Naesens L. Clinical features and treatment of adenovirus infections[J]. Rev Med Virol, 2008, 18:357-374.
[2] Wu L, Zhou P, Ge X, et al. Deep RNA sequencing reveals complex transcriptional landscape of a bat adenovirus[J]. J Virol, 2013, 87:503-511.
[3] Gao WJ, Jin Y, Duan ZJ. Research progress in human adenovirus[J]. Chin J Virol (病毒学报), 2014, 30:193-200.
[4] Vassal-Stermann E, Mottet M, Ducournau C, et al. Mapping of adenovirus of serotype 3 fibre interaction to desmoglein 2 revealed a novel ‘non-classical’ mechanism of viral receptor engagement[J]. Sci Rep, 2018, 8:8381.
[5] Cheng L, Huang X, Li X, et al. Cryo-EM structures of two bovine adenovirus type 3 intermediates[J]. Virology, 2014, 450-451:174-181.
[6] Chen NN, Xiang DX, Zheng CL. Adenovirus and its research progress[J]. J Dalian Med Univ (大连医科大学学报), 2010, 32:586-590.
[7] Johansson S, Nilsson E, Qian W, et al. Design, synthesis, and evaluation of N-acyl modified sialic acids as inhibitors of adenoviruses causing epidemic keratoconjunctivitis[J]. J Med Chem, 2009, 52:3666-3678.
[8] Kaneko H, Mori S, Shigeta S, et al. Antiviral effect of sulfated sialyl lipid against a clinical strain of adenovirus[J]. Nippon Ganka Gakkai Zasshi, 2003, 107:196-201.
[9] Johansson SM, Arnberg N, Elofsson M, et al. Multivalent HSA conjugates of 3'-sialyllactose are potent inhibitors of adenoviral cell attachment and infection[J]. Chembiochem, 2005, 6:358-364.
[10] Johansson SM, Nilsson EC, Elofsson M, et al. Multivalent sialic acid conjugates inhibit adenovirus type 37 from binding to and infecting human corneal epithelial cells[J]. Antiviral Res, 2007, 73:92-100.
[11] Aplander K, Marttila M, Manner S, et al. Molecular wipes:application to epidemic keratoconjuctivitis[J]. J Med Chem, 2011, 54:6670-6675.
[12] Spjut S, Qian W, Bauer J, et al. A potent trivalent sialic acid inhibitor of adenovirus type 37 infection of human corneal cells[J]. Angew Chem Int Ed, 2011, 50:6519-6521.
[13] Caraballo R, Saleeb M, Bauer J, et al. Triazole linker-based trivalent sialic acid inhibitors of adenovirus type 37 infection of human corneal epithelial cells[J]. Org Biomol Chem, 2015, 13:9194-9205.
[14] Lenaerts L, Naesens L. Antiviral therapy for adenovirus infections[J]. Antiviral Res, 2006, 71:172-180.
[15] Pang YP, Xu K, Kollmeyer TM, et al. Discovery of a new inhibitor lead of adenovirus proteinase:steps toward selective, irreversible inhibitors of cysteine proteinases[J]. FEBS Lett, 2001, 502:93-97.
[16] Mac SA, Grosche P, Ellis D, et al. Discovery and structure-based optimization of adenain inhibitors[J]. ACS Med Chem Lett, 2014, 5:937-941.
[17] Grosche P, Sirockin F, Mac Sweeney A, et al. Structure-based design and optimization of potent inhibitors of the adenoviral protease[J]. Bioorg Med Chem Lett, 2015, 25:438-443.
[18] Wang H, Wu QP. Studies in anti-virus nucleoside analogues[J]. Life Sci Instrum (生命科学仪器), 2006, 4:11-14.
[19] Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues[J]. Antimicrob Agents Chemother, 2005, 49:1010-1016.
[20] Yi H, Li ZR. Cidofovir-an antiviral agent[J]. Food Drug (食品与药品), 2005, 7:15-18.
[21] De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections[J]. Trends Pharmacol Sci, 2002, 23:456-458.
[22] Andrei G, Topalis D, Schutter TD, et al. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia[J]. Antiviral Res, 2015, 114:21-46.
[23] Fang SS, Zhang S, Cao GY. Advances in the study of the nucleoside antiviral drug cidofovir[J]. China Pharm (中国药房), 2016, 21:3022-3024.
[24] Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro[J]. Antimicrob Agents Chemother, 2002, 46:2381-2386.
[25] Gao MY, Liu HT, Lian YF, et al. Research progress in prodrugs of acyclic nucleoside phosphonates antiviral agents[J]. Chin J Org Chem (有机化学), 2019, 39:974-981.
[26] Hostetler KY. Synthesis and early development of hexadecyloxypropylcidofovir:an oral antipoxvirus nucleoside phosphonate[J]. Viruses, 2010, 2:2213-2225.
[27] Uckun FM, Pendergrass S, Qazi S, et al. Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus[J]. Cheminform, 2004, 39:225-234.
[28] Nikitenko NA, Gureeva ES, Ozerov AA, et al. 1-(4-Phenoxybenzyl) 5-aminouracil derivatives and their analogues-novel inhibitors of human adenovirus replication[J]. Acta Nat, 2018, 10:58-64.
[29] Sanchez-Cespedes J, Moyer CL, Whitby LR, et al. Inhibition of adenovirus replication by a trisubstituted piperazin-2-one derivative[J]. Antiviral Res, 2014, 108:65-73.
[30] Sánchez-Céspedes J, Martínez-Aguado P, Vega-Holm M, et al. New 4-acyl-1-phenylaminocarbonyl-2-phenylpiperazine derivatives as potential inhibitors of adenovirus infection. Synthesis, biological evaluation and structure-activity relationships[J]. J Med Chem, 2016, 59:5432-5448.
[31] Mazzotta S, Marrugal-Lorenzo JA, Vega-Holm M, et al. Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents[J]. Eur J Med Chem, 2020, 185:111840.
[32] Öberg CT, Strand M, Andersson EK, et al. Synthesis, biological evaluation, and structure-activity relationships of 2-[2-(benzoylamino)benzoylamino]benzoic acid analogues as inhibitors of adenovirus replication[J]. J Med Chem, 2012, 55:3170-3181.
[33] Andersson EK, Strand M, Edlund K, et al. Small-molecule screening using a whole-cell viral replication reporter gene assay identifies 2-{[2-(benzoylamino)benzoyl]amino}-benzoic acid as a novel antiadenoviral compound[J]. Antimicrob Agents Chemother, 2010, 54:3871-3877.
[34] Kang D, Zhang H, Zhou Z, et al. First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via ‘privileged scaffold’ refining approach[J]. Bioorg Med Chem Lett, 2016, 26:5182-5186.
[35] Li L, Santarsiero BD, Bouvier MJ. Structure of the adenovirus type 4(species E) E3-19K/HLA-A2 complex reveals species-specific features in MHC class I recognition[J]. J Immunol, 2016, 197:1399-1407.
[36] Ren J, Dsouza NR, Deng H, et al. Discovery of small molecule inhibitors of adenovirus by disrupting E3-19K/HLA-A2 interactions[J]. Bioorg Med Chem Lett, 2018, 28:2837-2841.
[37] Shi LQ, Yang ZQ, He J, et al. Antiviral effect of arbidol hydrochloride on adenovirus type 7 in vitro[J]. Med J Wuhan Univ (武汉大学学报医学版), 2006, 27:66-68.
[38] Sharma P, Martis PC, KJDA Excoffon. Adenovirus transduction:more complicated than receptor expression[J]. Virology, 2017, 502:144-151.
[39] Marrugal-Lorenzo JA, Serna-Gallego A, Berastegui-Cabrera J, et al. Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections[J]. Sci Rep, 2019, 9:17. https://doi.org/10.1038/s41598-018-37290-3.
[40] Xu JM, Berastegui-Cabrera J, Chen HY, et al. Structure-activity relationship studies on diversified salicylamide derivatives as potent inhibitors of human adenovirus infection[J]. J Med Chem, 2020, 63:3142-3160.
[41] Shang L, Qu ZY, Ning LL, et al. The anti-adenovirus effect of astragaloside IV in vitro[J]. Chin Pharmacol Bull (中国药理学通报), 2013, 29:854-858.
[42] Yang Y, Peng X, Zhu N, et al. Antiviral activities of flavonoids extracted from the core of lichi chinensis against adenovirus in vitro[J]. Med J Wuhan Univ (武汉大学学报医学版), 2014, 35:41-45.
[43] Karimi A, Moradi MT, Alidadi S, et al. Anti-adenovirus activity, antioxidant potential, and phenolic content of black tea (Camellia sinensis Kuntze) extract[J]. J Complement Integr Med, 2016, 13:357-363.
[44] Shang L, Qu ZY, Wei FX, et al. Advances in studies on anti-adenovirus of Chinese materia medica and its active components[J]. Chin Tradit Herb Drugs (中草药), 2012, 43:2071-2076.
1.魏粉菊, 马悦, 俞霁, 贾海永, 刘新泳, 展鹏.基于新靶标的HBV抑制剂研究进展(2):RNase H及其他靶标[J]. 药学学报, 2020,55(4): 566-574
2.魏文秀, 荆兰兰, 刘新泳, 展鹏.抗疱疹病毒药物化学研究新进展[J]. 药学学报, 2020,55(4): 575-584
3.李敬, 刘新泳, 展鹏.人巨细胞病毒抑制剂研究进展[J]. 药学学报, 2020,55(4): 585-596
4.修思雨, 张健, 鞠翰, 贾瑞芳, 黄兵, 展鹏, 刘新泳.抗流感病毒药物靶标及其小分子抑制剂的研究进展[J]. 药学学报, 2020,55(4): 611-626
5.宋淑, 高萍, 展鹏, 刘新泳.丙型肝炎病毒抑制剂研究进展[J]. 药学学报, 2020,55(4): 652-668
6.周忠霞, 孙林, 康东伟, 陈子慧, 唐苗苗, 李思雨, 展鹏, 刘新泳.具有新作用机制的HIV-1逆转录酶抑制剂研究进展[J]. 药学学报, 2018,53(5): 691-700
7.霍志鹏, 左晓芳, 康东伟, 展鹏, 刘新泳.抗艾滋病药物新靶标及其小分子抑制剂的研究进展[J]. 药学学报, 2018,53(3): 356-374